A new report from Quest Diagnostics, reveals physician and US adult perspectives on the current and future landscape of dementia and Alzheimer's disease (AD) evaluation, testing, treatment and care. Findings highlight the important role diagnostics may play in the next era of AD.
Introducing QUEST AD-DetectTM Amyloid Beta 42/40 ratio, now available. Analytically validated and less invasive,2 this testing solution can help evaluate patients, inform potential treatment decisions and monitor patients over time.
Learn moreHear from Dr Stephen Salloway and Dr Michael Racke as they discuss the current opportunities and challenges in diagnosing Alzheimer's Disease, the emerging role of blood-based biomarkers in AD screening and monitoring, and new diagnostic pathways.
Watch nowAlzheimer's can be difficult to diagnose. ADmark® Phospho-Tau/Total Tau/Aβ42 Analysis and Interpretation, includes a set of 3 biomarkers that differentiates Alzheimer's disease (AD) from other forms of dementia.3
Learn moreExplore our testing solutions and see how we can work together to bring patients to the end of their diagnostic journey.
Find a test1. Quest Advanced Neurology. The Coming Alzheimer's Disease Healthcare Revolution: U.S. Physician and Adult Perspectives on the Future of Diagnostics and Treatment (2022)
2. Data on file. Quest Diagnostics; 2022.
3. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease. Arch Gen Psychiatry. 2004;61(1):95-102. doi:10.1001/ archpsyc.61.1.95
Image content features a model and is intended for illustrative purposes only.
Test codes may vary by location. Please contact your local laboratory for more information.